Ischemia-Reperfusion Injury Mechanisms and Treatments

Ischaemia-reperfusion injury arises when blood flow is restored to previously oxygen-deprived tissue, paradoxically triggering a cascade of cellular damage. During the ischaemic phase, ATP depletion, ionic disturbances and acidosis compromise membrane integrity and mitochondrial function. Subsequent reperfusion elicits a burst of reactive oxygen species (ROS), calcium overload, endothelial activation and recruitment of inflammatory cells, notably neutrophils, which exacerbate microvascular obstruction and trigger apoptotic and necrotic pathways. Therapeutic strategies encompass mechanical approaches such as ischaemic pre-, post- and remote conditioning, metabolic modulation to preserve ATP stores, and pharmacological interventions targeting oxidative stress, mitochondrial permeability transition pores, inflammatory mediators and cell-survival signalling. Recent advances include engineered nanozymes for in situ ROS clearance and reappraisal of β-adrenergic antagonists as modulators of immune cell behaviour. These developments offer promise across cardiovascular disease, organ transplantation and peripheral vascular disorders, emphasising translation from mechanistic insights to clinical benefit.

Research from Nature Portfolio

Recent studies have introduced a single-atom platinum nanozyme that mimics multiple antioxidant enzymes with exceptional catalytic efficiency. In vitro and in vivo experiments demonstrate potent scavenging of superoxide and hydrogen peroxide, restoration of cellular redox homeostasis and prevention of cardiomyocyte apoptosis following reperfusion. The nanozyme exhibits favourable biocompatibility and stability, suggesting a versatile platform for targeted delivery to injured myocardium. In parallel, work on metoprolol has shifted attention from cardiomyocytes to the haematopoietic compartment: the β₁-adrenergic antagonist was shown to inhibit neutrophil–platelet interactions during early reperfusion, thereby reducing microvascular obstruction and infarct size. These findings redefine protective mechanisms of a long-established drug and highlight immune cells as direct therapeutic targets in reperfusion injury.

Ischemia-Reperfusion Injury Mechanisms and Treatments publication trend

The graph below shows the total number of articles in ischemia-reperfusion injury mechanisms and treatments across all publications each year (not limited to Nature Index journals).

Technical terms

Ischaemia: Reduction or cessation of blood supply to tissue, depriving cells of oxygen and nutrients.

Reperfusion injury: Additional tissue damage caused by the restoration of blood flow after ischaemia, involving oxidative stress and inflammation.

Reactive oxygen species (ROS): Highly reactive molecules derived from oxygen, such as superoxide and hydrogen peroxide, that can damage cellular structures.

Preconditioning: A protective strategy involving brief, non-lethal ischaemia episodes that render tissue more resistant to subsequent prolonged ischaemia.

Nanozyme: A nanomaterial engineered to mimic natural enzyme activities, particularly for catalysing the degradation of ROS.

Neutrophil–platelet interaction: Adhesive and signalling events between white blood cells and platelets that contribute to microvascular occlusion and inflammation during reperfusion.

References

1. Protective effects of Pt-N-C single-atom nanozymes against myocardial ischemia-reperfusion injury. Nature Communications (2024).
2. Neutrophil stunning by metoprolol reduces infarct size. Nature Communications (2017).
3. Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery. Basic Research in Cardiology (2016).
4. Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial. The Lancet (2019).
5. Role of Oxidative Stress in Reperfusion following Myocardial Ischemia and Its Treatments. Oxidative Medicine and Cellular Longevity (2021).
6. Ischemia/Reperfusion Injury Revisited: An Overview of the Latest Pharmacological Strategies. International Journal of Molecular Sciences (2019).